Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?-Reference-Cited by-同舟云学术

Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

Published:2015-07-02 Issue:9 Volume:14 Page:1445-1455
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Husain Nazik Elmalaika,Hassan Abdallah Tarig,Elmadhoun Wadie M,Ahmed Mohamed H

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14740338.2015.1063613

Reference70 articles.

1. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)

2. Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism

3. Statins UpregulatePCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

4. Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current strategies for nonalcoholic fatty liver disease treatment (Review);International Journal of Molecular Medicine;2024-08-08

2. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?;Current Vascular Pharmacology;2021-09

3. The Role of Lipid and Lipoprotein Metabolism in Non‐Alcoholic Fatty Liver Disease;Children;2017-06-06

4. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe;Clinical Medicine Insights: Case Reports;2017-01-01

5. Non-alcoholic fatty liver disease and dyslipidemia: An update;Metabolism;2016-08